1-4 of 4
Helen Collins
Close
Sort by
Journal Articles

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Timothy Hughes, Michael Mauro, Susan Branford, Wei Deng, Qi Wang, Helen Collins, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6780–6781.
https://doi.org/10.1182/blood-2022-170401
Published: 2022
Journal Articles

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Vikas Gupta, MD FRCP, FRCPath, Ruben A. Mesa, Michael W Deininger, MD PhD, Candido E. Rivera, MD, Shireen Sirhan, MD FRCP, Srdan Verstovsek, MD, Yafeng Zhang, PhD, Yuanyuan Xiao, PhD, Helen Collins, MD, Kevin Kwei, Adarsh Joshi, PhD, Carrie Baker Brachmann, PhD
Journal: Blood
Blood (2015) 126 (23): 1600.
https://doi.org/10.1182/blood.V126.23.1600.1600
Published: 2015
Journal Articles

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Demi Niforos, MS, Mark Kowalski, MD, PhD, Linda M Bavisotto, MD, Jun Kawashima, MD, Susie Jun, MD, PhD, Helen Collins, MD, Srinivasan Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 1590.
https://doi.org/10.1182/blood.V122.21.1590.1590
Published: 2013
Journal Articles

HIF-1 regulates heritable variation and allele expression phenotypes of the macrophage immune response gene SLC11A1 from a Z-DNA–forming microsatellite

Henry K. Bayele, Carole Peyssonnaux, Alexandra Giatromanolaki, Wagner W. Arrais-Silva, Hiba S. Mohamed, Helen Collins, Selma Giorgio, Michael Koukourakis, Randall S. Johnson, Jenefer M. Blackwell, Victor Nizet, Surjit Kaila S. Srai
Journal: Blood
Blood (2007) 110 (8): 3039–3048.
https://doi.org/10.1182/blood-2006-12-063289
Published: 2007
Includes: Supplemental data